Morphic Holding, Inc. (MORF)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 27.97 |
| Open | 28.41 |
| Bid | 28.65 x 400 |
| Ask | 28.81 x 200 |
| Day's Range | 28.09 - 29.17 |
| 52 Week Range | 19.34 - 63.08 |
| Volume | |
| Avg. Volume | 455,857 |
| Market Cap | 1.438B |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.60 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 56.00 |
Simply Wall St.Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review
Insights into Financial Performance and Strategic Developments
GlobeNewswireMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda
© 2024 Yahoo. All rights reserved.